Ab1198 Copd Outcomes in Individuals With Scleroderma Compared to General Population: A Population Based Study

Background: Chronic obstructive pulmonary disease (COPD) contributes to 3 million annual deaths. Linked to chronic inflammation and respiratory symptoms, COPD's impact on morbidity and mortality is substantial. Recent research points to autoimmune diseases heightening COPD risk. Among these, scleroderma stands out—a rare autoimmune disorder affecting multiple organs. Objectives: To investigate the COPD outcomes in individuals with Scleroderma compared to general population. Methods: National Inpatient Database was queried from 2015 to 2019, with Principal Diagnosis of COPD and secondary diagnosis was used for Scleroderma using ICD-10 codes. Data was appended using latest HCUP guidelines. Univariate analysis with student t test and chi square was performed, and a multivariate regression model was created to generate odds ratio adjusting for hospital level confounders and various co-morbidities. P-value of <0.05 was considered significant, and all the analysis was performed using STATA-MP v 14.2. Results: Demographic data comparing COPD outcomes in individuals with Scleroderma to the general population reveals significant differences. In the Scleroderma group (n=2100), the mean age is 66.61 years, slightly lower than the general COPD population (n=2538704) with a mean age of 68.18 years (p<0.0001). Notably, Scleroderma patients exhibit a higher proportion of females (83.81% vs. 57.7%, p<0.0001) and diverse racial distribution (p<0.0001). The Charlson Comorbidity Index, ZIP code income, and insurance type also exhibit significant variations (all p<0.0001). Univariate and multivariate analyses, assessing COPD outcomes in Scleroderma individuals, reveal no significant association with mortality, length of stay, total charges, or ventilation. Descriptive statistics indicate marginal differences in outcomes between the two groups, with a slightly higher percentage of deaths and longer length of stay in the Scleroderma cohort. Conclusion: The research reported high mortality and morbidity rates in COPD patients suffering from Scleroderma. However, due to the complexity of these conditions, additional research is required to fully comprehend the influence of Scleroderma on COPD.REFERENCES: NIL. Acknowledgements: NIL. Disclosure of Interests: None declared.